SCHEMBL2510171

SCHEMBL2510171

CCc1nc2cnc3ccccc3c2n1CCCCNC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.46
PIM3 Q86V86 1/20 0.46
TLR7 Q9NYK1 6/20 0.45
TLR8 Q9NR97 1/20 0.44
STING1 Q86WV6 2/20 0.44
BRD4 O60885 3/20 0.43
DRD2 P14416 2/20 0.42
GBA1 P04062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968312 0.93 TLR7 (0.49) PIM1PIM3TLR7TLR8STING1
SCHEMBL24723244 0.92 TLR7 (0.54) PIM1PIM3TLR7TLR8
SCHEMBL22359571 0.91 TLR7 (0.54) PIM1PIM3TLR7TLR8STING1
SCHEMBL3970752 0.90 TLR7 (0.52) TLR7
SCHEMBL5110579 0.90 TLR7 (0.44) TLR7TLR8GBA1
SCHEMBL1232968 0.89 TLR7 (0.45) PIM1PIM3TLR7TLR8STING1
SCHEMBL8127843 0.89 BRD4 (0.48) PIM1PIM3TLR7STING1BRD4
SCHEMBL2743673 0.89 STING1 (0.45) PIM1PIM3TLR7TLR8STING1
SCHEMBL4551314 0.89 TLR7 (0.54) TLR7
SCHEMBL14288481 0.88 MEN1 (0.41) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9908880-B2 Substituted imidazoquinolines 4SC AG (DE) 2018-03-06 US disclosed
US-9908880-B2 Substituted imidazoquinolines 4SC AG (DE) 2018-03-06 US disclosed
EP-2386557-B1 Novel substituted imidazoquinolines 4SC DISCOVERY GMBH (DE) 2018-01-10 EP disclosed
US-20170029422-A1 NOVEL SUBSTITUTED IMIDAZOQUINOLINES 4SC AG (DE) 2017-02-02 US disclosed
US-20170029422-A1 NOVEL SUBSTITUTED IMIDAZOQUINOLINES 4SC AG (DE) 2017-02-02 US disclosed
US-9446040-B2 Substituted imidazoquinolines 4SC AG (DE) 2016-09-20 US disclosed
US-9446040-B2 Substituted imidazoquinolines 4SC AG (DE) 2016-09-20 US disclosed
US-20150335636-A1 NOVEL SUBSTITUTED IMIDAZOQUINOLINES 4SC AG (DE) 2015-11-26 US disclosed
US-20150335636-A1 NOVEL SUBSTITUTED IMIDAZOQUINOLINES 4SC AG (DE) 2015-11-26 US disclosed
US-9073913-B2 Substituted imidazoquinolines 4SC AG (DE) 2015-07-07 US disclosed
CN-1812789-A Sulfonamide substituted imidazoquinolines 3M INNOVATION CO LTD (US) 2006-08-02 CN disclosed
EP-1638566-A2 SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2006-03-29 EP disclosed
US-20050197358-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2005-09-08 US disclosed
US-6924293-B2 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-08-02 US disclosed
US-6888000-B2 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-05-03 US disclosed
WO-2005003064-A2 SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-01-13 WO disclosed
WO-2005003065-A2 SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-01-13 WO disclosed
US-20040132762-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-08 US disclosed
US-20040106638-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-06-03 US disclosed
US-6677349-B1 INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335636-A1 NOVEL SUBSTITUTED IMIDAZOQUINOLINES TLR7, TLR1, TLR4 PIM1 1573/4885PIM3 2025/4885TLR7 1/4885
US-20050197358-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 PIM1 130/4885PIM3 257/4885TLR7 59/4885
US-20170029422-A1 NOVEL SUBSTITUTED IMIDAZOQUINOLINES TLR7, TLR1, TLR4 PIM1 1573/4885PIM3 2025/4885TLR7 1/4885
US-20040132762-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 PIM1 130/4885PIM3 257/4885TLR7 59/4885
US-20040106638-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 PIM1 130/4885PIM3 257/4885TLR7 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.